ICH E6(R3) Sparks Urgency, But Real Change Has Barely Begun
The 2025 Veeva Clinical Operations Oversight Forum in Copenhagen brought together sponsors, CROs, and technology partners to examine one...
Tokenization and Real-World Data Linkage: A New Era in Patient-Centric Trials
At the 2025 Indegene Digital Summit, a session hosted by Indegene and Datavant, senior leaders Mayank Rizada and Melissa...
New GCP Revision Redefines Vendor Oversight and Digital Accountability
At SCOPE Europe 2025, experts underscored that the revised International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guideline,...
How Big Pharma is Rethinking Regulatory Operations in the Digital Era
At the 2025 Indegene Digital Summit, a high-level panel of regulatory executives from Pfizer, Novartis, and Boehringer Ingelheim gathered...
Europe’s Clinical Trial Exodus: Can the Region Regain Its Competitive Edge?
At the SCOPE 2025 Europe conference, during a panel titled, “Trials Are Leaving Europe — Can We Bring Them...
AI at the Crossroads: FDA and Industry Chart a Risk-Based Path for Drug Development
At a landmark FDA workshop on artificial intelligence (AI) in drug development, regulators and industry leaders outlined a vision...
Embedding Patient Advocacy in R&D: The Next Frontier in Pharma Collaboration
At a recent industry panel at SCOPE Europe, experts from advocacy organizations and pharmaceutical companies explored a striking imbalance:...
Pfizer’s AI-Powered Feasibility and Cost Efficiency: The Future of Clinical Trial Recruitment
At the 2025 SCOPE Europe conference, industry leaders examined how artificial intelligence (AI) is reshaping feasibility assessment and patient...
Using Behavioral AI to Predict and Prevent Clinical Trial Dropouts
At SCOPE Europe 2025, we spoke with Dominique Demolle, CEO of Cognivia, about how behavioral AI is helping sponsors...
Risk-Based Oversight Redefined: How E6R3 is Reshaping Vendor Governance
At the SCOPE Europe 2025 conference, industry experts underscored how ICH E6(R3) is transforming the way sponsors approach vendor...